Prospective study of human papillomavirus and risk of cervical adenocarcinoma.
Human papillomaviruses (HPV) are established as a major cause of cervical carcinoma. However, causality inference is dependent on prospective evidence showing that exposure predicts risk for future disease. Such evidence is available for squamous cell carcinoma, but not for cervical adenocarcinoma. We followed a population-based cohort of 994,120 women who participated in cytological screening in Sweden for a median of 6.7 years. Baseline smears from women who developed adenocarcinoma during follow-up (118 women with in situ disease and 164 with invasive disease) and their individually matched controls (1,434 smears) were analyzed for HPV using PCR. Conditional logistic regression was used to estimate odds ratios (OR) of future adenocarcinoma with 95% confidence intervals (CI). Being positive for HPV 16 in the first cytologically normal smear was associated with increased risks for both future adenocarcinoma in situ (OR: 11.0, 95% CI: 2.6-46.8) and invasive adenocarcinoma (OR: 16.0, 95% CI: 3.8-66.7), compared to being negative for HPV 16. Similarly, an HPV 18 positive smear was associated with increased risks for adenocarcinoma in situ (OR: 26.0, 95% CI: 3.5-192) and invasive adenocarcinoma (OR: 28.0, 95% CI: 3.8-206), compared to an HPV 18 negative smear. Being positive for HPV 16/18 in 2 subsequent smears was associated with an infinite risk of both in situ and invasive adenocarcinoma. In conclusion, infections with HPV 16 and 18 are detectable up to at least 14 years before diagnosis of cervical adenocarcinoma. Our data provide prospective evidence that the association of HPV 16/18 with cervical adenocarcinoma is strong and causal.
Dahlström
Lisen Arnheim
LA
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. lisen.arnheim.dahlstrom@ki.se
Ylitalo
Nathalie
N
Sundström
Karin
K
Palmgren
Juni
J
Ploner
Alexander
A
Eloranta
Sandra
S
Sanjeevi
Carani B
CB
Andersson
Sonia
S
Rohan
Thomas
T
Dillner
Joakim
J
Adami
Hans-Olov
HO
Sparén
Pär
P
D000230:Adenocarcinoma / Q000473:pathology / Q000821:virology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000473:pathology / Q000821:virology*; D016022:Case-Control Studies; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000473:pathology / Q000821:virology*; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D013548:Sweden; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000821:virology*; D055815:Young Adult
D004279:DNA, Viral
J Natl Cancer Inst. 2008 May 7;100(9):622-9
18445828
Biometrics. 1988 Jun;44(2):355-67
3390504
Br J Cancer. 1999 Sep;81(1):159-66
10487628
J Natl Cancer Inst. 2006 Mar 1;98(5):303-15
16507827
Br J Cancer. 1995 Aug;72(2):498-505
7640239
Anal Quant Cytol Histol. 1995 Aug;17(4):221-9
8526946
Cancer Res. 2000 Nov 1;60(21):6027-32
11085523
Int J Cancer. 2000 May 1;86(3):429-35
10760834
Int J Gynecol Cancer. 2006 May-Jun;16(3):1025-31
16803480
Int J Cancer. 1998 Feb 9;75(4):536-45
9466653
Cancer Detect Prev. 2004;28(6):461-4
15582270
Am J Pathol. 2000 Oct;157(4):1055-62
11021808
J Clin Microbiol. 2009 Mar;47(3):541-6
19144817
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9
16172231
J Pathol. 2003 Dec;201(4):535-43
14648656
Cancer Causes Control. 1997 Sep;8(5):755-63
9328198
Br J Cancer. 2005 Nov 28;93(11):1301-4
16265348
Eur J Cancer. 2001 Jan;37(2):246-50
11166153
Br J Cancer. 2006 Jan 16;94(1):171-5
16404371
Int J Cancer. 2007 Feb 15;120(4):885-91
17131323
Int J Cancer. 2009 Aug 1;125(3):525-9
19449379
J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62
9049358
Br J Cancer. 2003 Jan 13;88(1):63-73
12556961